Last $0.36 USD
Change Today -0.0161 / -4.28%
Volume 365.6K
ONCS On Other Exchanges
Symbol
Exchange
OTC US
As of 12:34 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Key Developments

Heat Biologics, Inc. and OncoSec Medical Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms

Heat Biologics, Inc. and OncoSec Medical Inc. announced that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company. Under the agreement, Heat and OncoSec will jointly evaluate the preclinical efficacy of Heat's proprietary gp-96-Ig based ImPACT immunotherapy platform using OncoSec's core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform. Heat and OncoSec are exploring this combination as part of their ongoing strategy to expand the application of their technologies to benefit cancer patients with unmet medical needs. Heat has two clinical stage programs based on the ImPACT platform, viagenpumatucel-L (HS-110 [2]) in a Phase 2 clinical trial in patients with non-small cell lung cancer and vesigenurtacel-L (HS-410 [3]) in a Phase 2 clinical trial in patients with non-muscle invasive bladder cancer. OncoSec's core platform, ImmunoPulse, which is based on the intratumoral delivery of DNA IL-12, is currently in Phase 2 clinical trials, investigating the approach for treatment of metastatic melanoma, head and neck cancer, triple negative breast cancer, and cutaneous T-cell lymphoma.

OncoSec Medical Incorporated and ARE-SD Region No. 18, LLC Enter into Lease Agreement for Corporate Headquarters and Research and Development Laboratory

On December 31, 2014, OncoSec Medical Incorporated (the Company) and ARE-SD Region No. 18, LLC (the Landlord) entered into a Lease Agreement (the Lease Agreement). Pursuant to the Lease Agreement, the Company has leased certain premises of approximately 33,928 rentable square feet located at 5820 Nancy Ridge Drive, San Diego, California to serve as the company's corporate headquarters and research and development laboratory. The term of the lease agreement is expected to commence on or about October 1, 2015 (the Commencement Date), and expires one hundred twenty (120) months after the Commencement Date.

OncoSec Medical Incorporated Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM

OncoSec Medical Incorporated Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.

Oncosec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse

OncoSec Medical Inc. has initiated a Phase II trial in squamous cell carcinoma of the head and neck (SCCHN) using its proprietary ImmunoPulse platform. The multicenter study is scheduled to be initiated in the first quarter of 2015, with the University of California San Francisco, under the direction of Dr. Alain Algazi as the first site of enrollment. The study will enroll patients with treatment-refractory metastatic and unresectable SCCHN, regardless of HPV status. Eligible patients will receive up to nine cycles of IL-12 ImmunoPulse at six-week intervals and will be followed for clinical response and safety. The first stage of the study will enroll 20 patients with measurable disease. If three or more objective responses are observed, an additional 11 patients with measurable disease will be treated, for a total of 31 patients. The primary endpoint for this study will be best overall response by RECIST 1.1.

Oncosec Medical Inc. Announces Earnings Results for the First Quarter Ended October 31, 2014

OncoSec Medical Inc. announced earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported a net loss of $4.1 million, or $0.02 per share, compared to a net loss of $2.1 million, or $0.01 per share, for the same period last year. There were no revenues for quarter ended October 31, 2014 or October 31, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.36 USD -0.0161

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.